Compare IDEXX Laboratories, Inc. (IDXX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Wells Fargo & Co — how do they compare? IDEXX Laboratories, Inc. trades at $519.64 (market cap $40.43B), while Wells Fargo & Co trades at $83.64 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 6.1× IDEXX Laboratories, Inc.'s market cap, and Wells Fargo & Co pays a 2.44% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Wells Fargo & Co for 87 Days on average.
| IDXX | WFC | |
|---|---|---|
Market Cap | $40.43B | $248.06B |
Volume | 692,164 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $766.68 | $96.40 |
52-Week Low | $504.70 | $73.42 |
Typical Hold Time | 46 Days | 87 Days |
Enterprise Value | $41.32B | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Wells Fargo (WFC) trades at $83.16, up 3.61% today, showing resilience amid a bearish technical signal. The stock benefits from strong profitability with a 25.97% net margin and a modest P/E of 11.92, indicating potential undervaluation relative to earnings. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and a renewed mortgage servicing agreement with Intercontinental Exchange (Business Wire, 2026-09-29).
The outlook is cautiously optimistic, supported by analyst consensus targets near $99.13 and improving net interest income prospects from Fed rate hikes. Key risks include volatile cash flows, with 2025 operating cash flow negative $19.0B, and execution challenges amid leadership transitions like the chief risk officer's retirement (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
